A Big IDEA: Landmark Project Spearheaded by American Association of Clinical Endocrinologists to Advance Universal Awareness and Understanding of Continuous Glucose Monitoring

Monday, November 19, 2018 3:19 pm EST

Dateline:

JACKSONVILLE, Fla.
"These materials will provide the uniformity necessary for CGM use to reach its full potential"

What began in 2014 as a series of American Association of Clinical Endocrinologists (AACE)-initiated public consensus conferences to examine the growing body of evidence supporting glucose monitoring benefits and develop strategies for overcoming barriers to continuous glucose monitoring (CGM) use has grown into a full-blown, far-reaching program that aims to change the course of optimal diabetes care for patients.

Known as IDEA (Innovating Decisions and Empowering Action in Diabetes), the program’s work began in early 2018 after assembling an unprecedented collaborative of organizations in the diabetes health care space.

Program participants include AACE, the American Association of Diabetes Educators (AADE), the American College of Clinical Pharmacy (ACCP), the American Diabetes Association (ADA), the American Society of Endocrine Physician Assistants (ASEPA), the College Diabetes Network (CDN), the Diabetes Patient Advocacy Coalition, the Endocrine Society, the Juvenile Diabetes Research Foundation (JDRF), The Leona M. and Harry B. Helmsley Charitable Trust, the International Diabetes Center (IDC), T1D Exchange and The diaTribe Foundation/Close Concerns.

The IDEA project’s mission is to ensure all health care professionals and patients have the information and tools they need to make the most informed clinical decisions possible about CGM use. The IDEA project will achieve this goal through the creation and delivery of comprehensive, easy-to-understand, user-appropriate educational and awareness materials for distribution to stakeholders throughout  the diabetes care ecosystem.

“These materials will provide the uniformity necessary for CGM use to reach its full potential,” notes AACE President Daniel Hurley, MD, FACE.

“Key to advancement of the project was buy-in and agreement from each CGM device manufacturer to develop a unified report that could be used for educational purposes by all parties, from endocrinologists to primary care physicians to diabetes educators and so forth, so that the patient could be properly educated and caregivers could define what comes next in that patient’s treatment routine,” says George Grunberger, MD, FACP, FACE, primary architect of the AACE consensus conferences and chair of the IDEA steering committee. Despite the proprietary nature of CGM technology, all of the companies in the arena agreed to the proposition.

Another vital development was the International Diabetes Center (IDC) agreeing to be a part of the effort, as the organization owns the copyright to the Ambulatory Glucose Profile, the report forming the backbone for the IDEA unified CGM report.

“Right now, there’s a lot of work to be done,” Dr. Grunberger adds. “We are finally organizing all these pieces and gathering content for the learning program launch, which is planned in late 2018.”

About the American Association of Clinical Endocrinologists (AACE)

The American Association of Clinical Endocrinologists (AACE) represents more than 7,000 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. A majority of AACE members are certified in endocrinology, diabetes and metabolism and concentrate on the treatment of patients with endocrine and metabolic disorders including diabetes, thyroid disorders, osteoporosis, growth hormone deficiency, cholesterol disorders, hypertension and obesity. Visit our site at www.aace.com.